21 May 2009
Immunosuppression sparing in patient with severe sepsis post renal transplant
K Kotfïs, M Zukowski, J Biernawska, M Zegan, R Bohatyrewicz, A GreczanAnn Transplant 2009; 14(1): 75-75 :: ID: 880476
Abstract
Background: In patients after a renal transplant, life-long immunosuppression is a part of absolutely required treatment to prevent acute graft rejection. Faced with severe infection or impending sepsis the immunosuppression further complicates treatment, especially in case of sepsis-induced secondary immunosuppression.
Case Report: We present a case of a 57-year old female (with h/o autosomal
dominant polycystic kidney disease, hypertension, secondary diabetes mellitus, end-stage chronic renal disease, post bilateral nephrectomy) who was admitted to ICU 2 months after a renal transplant with severe respiratory failure secondary to pneumonia. She subsequently developed septic shock with neutropenia. Routine microbiological screening showed E.coli ESBL (+) growth, patient was treated according to microbiology sensitivity. The immunosuppressive agents (tacrolimus, corticosteroids) were continued throughout the course of treatment to prevent acute graft rejection, mycophenolate mofetil was discontinued on admission to ICU. Despite multimodal approach (including HVCVVH, drotrecogin alfa infusion) patient died on the 4th day after admission (cardiac arrest, asystole).
Conclusions: Net state of immunosuppression is achieved as a balance between exposure to infectious agents (hospital or community sources) and overall immunosuppression level. This case raises one important issue. A question of the timing and extent of immunosuppression withdrawal: at the
diagnosis of severe infection, when the diagnosis of sepsis is made or when
neutropenia occurs in the course of sepsis?
Keywords: Immunosuppression, Kidney Transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






